← brief for 2026-08-10 · Slowing decline

Osteoactivin/GPNMB as a candidate biomarker of diabetic nephropathy in type 2 diabetes: associations with angiogenic and kidney injury biomarkers

Paper C Peer reviewed Observational

Key takeaways

This study looked at whether a protein called GPNMB (also called osteoactivin) could be a marker of kidney damage in type 2 diabetes. Higher levels lined up with other injury markers. It shows a link, not cause.

Who did this work

Mohamed Abu‐Farha (Dasman Diabetes Institute) · Sulaiman Marafie (Dasman Diabetes Institute) · Laila Alhemoud (Dasman Diabetes Institute) · Eman Al Shawaf (Dasman Diabetes Institute) · Reem Malek (Dasman Diabetes Institute) · Joud Almuharib (Dasman Diabetes Institute) · Sriraman Devarajan (Dasman Diabetes Institute) · Irina Al‐Khairi (Dasman Diabetes Institute) · PREETHI CHERIAN (Dasman Diabetes Institute) · Hamad Ali (Kuwait University) · Abdullah Faisal Almutairi (King Saud Medical City) · Ibrahim Taher (Jouf University)

Source

Indexed paper · OpenAlex — CKD concept sweep (DB seed + weekly delta) · 2026-08-06
https://doi.org/10.3389/fendo.2026.1908607